cabergoline (dostinex) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Results of in vitro studies demonstrate that cabergoline exerts a direct inhibitory effect on the secretion of prolactin by rat pituitary lactotrophs. It is FDA approved for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Common adverse reactions include constipation, nausea, dizziness, headache and fatigue. Cabergoline should not be administered concurrently with D-antagonists, such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide.   NCATS

Chemistry

  • SMILES: CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=C3C2=CC=C4)N(CC=C)C1
  • InChIKey: KORNTPPJEAJQIU-KJXAQDMKSA-N
  • Mol. Mass: 451.6043
  • ALogP: 3.19
  • ChEMBL Molecule:
    cabergoline  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0700 - $5.1163

Australia

$1.2537 - $5.1809
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea | 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea | 1-ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate | 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea | (8beta)-n-[3-(dimethylamino)propyl]-n-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide | (8r)-6-allyl-n-[3-(dimethylamino)propyl]-n-(ethylcarbamoyl)ergoline-8-carboxamide | cabaser | cabaseril | cabergolina | cabergoline | cabergoline diphosphate | cabergolinum | dostinex | fce 21336 | fce-21336 | galastop

Organizations (73)

Research & Development (65)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (33)

Approved Indications (5)


 

Acromegaly

Hyperprolactinemia (approved 2005)

Parkinson Disease

Pituitary Neoplasms

Prolactinoma (approved 2005)

Experimental Indications - Clinical Trial Phases 1-4 (32)


 

Abortion, Induced (Phase 4)

Acromegaly (Phase 4)

ACTH-Secreting Pituitary Adenoma (Phase 3)

Adenoma (Phase 3)

Atrial Fibrillation (Phase 4)

Body Weight (Phase 1/Phase 2)

Breast Neoplasms (Early Phase 1)

Cocaine-Related Disorders (Phase 2)

Cushing Syndrome (Phase 2)

Diabetes Mellitus (Phase 3)

Drug-Related Side Effects and Adverse Reactions (Phase 4)

Drugs, Generic (Phase 1)

Endometriosis (Phase 2)

Fertilization in Vitro (Phase 4)

Health Education (Phase 1)

Infertility (Phase 2/Phase 3)

Infertility, Female (Phase 4)

Ischemia (Phase 4)

Lactation Disorders (Phase 4)

Obesity (Phase 1/Phase 2)

Ovarian Diseases (Phase 3)

Ovarian Hyperstimulation Syndrome (Phase 3)

Parkinson Disease (Phase 4)

Pituitary ACTH Hypersecretion (Phase 3)

Pituitary Neoplasms (Phase 4)

Polycystic Ovary Syndrome (Phase 2)

Prolactinoma (Phase 4)

Reproductive Health (Phase 2)

Restless Legs Syndrome (Phase 3)

Scleroderma, Diffuse (Phase 3)

Substance-Related Disorders (Phase 2)

Tachycardia, Ventricular (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 61
  • # of Trial Organizations: 65

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue